Q-omics provides the consensus-scored TEX10 profile across patient tissues and cancer cell-line models. TEX10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TEX10 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TEX10 protein abundance shows 27,558 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where TEX10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX10 survival associations across molecular data types. TEX10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX10 RNA expression–survival associations across cancer types. High TEX10 expression shows unfavorable associations in ACC, BLCA, LIHC and ESCA, but favorable associations in KIRC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TEX10 RNA expression.
This table summarizes TEX10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TEX10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX10 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, STAD, LIHC and READ. The COAD box plot shows higher TEX10 RNA expression in tumor versus normal tissue (log2 FC = +1.346, t-test p < 0.001).
This table shows molecular features associated with TEX10 in patient tissues and cancer cell lines. In patient samples, TEX10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
